title: [Antiangiogenic therapy in Sorsby's fundus dystrophy without a mutation in the TIMP-3 gene].
abstract: METHODS
  The case is presented of a 32-year-old man referring to metamorphopsia and blurred vision in both eyes for 3 days. Best corrected visual acuity of 20/32 in the right eye and 20/25 in the left eye. Fundus examination revealed the presence of drusen-like deposits, suggestive of Sorsby's fundus dystrophy (SFD) and choroidal neovascularization (CNV) bilaterally. The patient received intravitreal ranibizumab. Visual acuity improved to 20/20 in both eyes at 6-months follow-up, and results of fundus examination showed complete regression of neovascularization. No mutations were found in the TIMP-3 gene.
  
  
  CONCLUSIONS
  The known mutations in TIMP-3 may not be extended to all patients with SFD. The use of intravitreal ranibizumab may be considered as a therapeutic option in CNV secondary to SFD.
authors.affiliation: Servicio de Oftalmología, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. sergioab@hotmail.com
authors.forename: S
authors.initials: S
authors.lastname: Copete-Piqueras
authors.forename: C
authors.initials: C
authors.lastname: Cava-Valenciano
authors.forename: I
authors.initials: I
authors.lastname: Flores-Moreno
authors.forename: A
authors.initials: A
authors.lastname: Moreno-Valladares
authors.forename: V
authors.initials: V
authors.lastname: Bautista Ruescas
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D009154:Mutation; D000069579:Ranibizumab; D019717:Tissue Inhibitor of Metalloproteinase-3 / Q000235:genetics
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C088390:TIMP3 protein, human; D019717:Tissue Inhibitor of Metalloproteinase-3; D000069579:Ranibizumab